Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma
Public ClinicalTrials.gov record NCT02408016. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase I/II Study in WT1-Expressing Non-small Cell Lung Cancer and Mesothelioma, Comparing Cellular Adoptive Immunotherapy With Polyclonal Autologous Central Memory to Naïve CD8+ T Cells That Have Been Transduced to Express a WT1-Specific T-Cell Receptor
Study identification
- NCT ID
- NCT02408016
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Enrollment
- 11 participants
Conditions and interventions
Conditions
- Advanced Pleural Malignant Mesothelioma
- HLA-A*0201 Positive Cells Present
- Recurrent Non-Small Cell Lung Carcinoma
- Recurrent Pleural Malignant Mesothelioma
- Stage III Non-Small Cell Lung Cancer AJCC v7
- Stage III Pleural Malignant Mesothelioma AJCC v7
- Stage IIIA Non-Small Cell Lung Cancer AJCC v7
- Stage IIIB Non-Small Cell Lung Cancer AJCC v7
- Stage IV Non-Small Cell Lung Cancer AJCC v7
- Stage IV Pleural Malignant Mesothelioma AJCC v7
- WT1 Positive
Interventions
- Aldesleukin Biological
- Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes Biological
- Cyclophosphamide Drug
- Laboratory Biomarker Analysis Other
- Therapeutic Conventional Surgery Procedure
Biological · Drug · Other + 1 more
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 21, 2015
- Primary completion
- Jun 29, 2020
- Completion
- Jun 29, 2020
- Last update posted
- Sep 12, 2021
2015 – 2020
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Fred Hutch/University of Washington Cancer Consortium | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02408016, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 12, 2021 · Synced May 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02408016 live on ClinicalTrials.gov.